NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Inspire Medical Systems, Inc. (NYSE: INSP) between August 6, 2024 and August 4, 2025, both dates inclusive (the “Class Period”), of the important January 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased Inspire Medical common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingenc ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Firefly Aerospace Inc. due to allegations of materially misleading business information issued to the investing public [1]. Group 1: Investigation and Legal Action - Shareholders who purchased Firefly Aerospace securities may be entitled to compensation through a contingency fee arrangement, with a class action being prepared to seek recovery of investor losses [2]. - The investigation follows a report from The Wall Street Journal indicating that Firefly Aerospace posted a wider loss and lower revenue in its latest quarter, leading to a significant stock price drop of 15.3% on September 23, 2025 [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions of dollars for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 [4].

Core Viewpoint - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which failed to meet its primary endpoint in a clinical study, leading to a significant drop in stock price [1]. Summary by Sections Allegations - The complaint alleges that aTyr Pharma provided overwhelmingly positive statements about Efzofitimod while concealing material adverse facts about its efficacy, particularly its ability to allow patients to taper steroid usage completely [1]. - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, specifically in the change from baseline in mean daily OSC dose at week 48 [1]. Stock Price Impact - Following the announcement of the disappointing study results, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking a decline of 83.2% in just one day [1]. Class Action Details - Shareholders who purchased shares of aTyr during the class period from November 7, 2024, to September 12, 2025, are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment [1][2]. - The deadline for shareholders to register for the class action is December 8, 2025, and there is no cost or obligation to participate [2].

Core Viewpoint - Rosen Law Firm is encouraging investors of Molina Healthcare, Inc. who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the December 2, 2025 deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Molina securities between February 5, 2025, and July 23, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 2, 2025 [3]. - The lawsuit claims that Molina failed to disclose several material adverse facts regarding its financial health, which misled investors [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a record settlement against a Chinese company and significant recoveries for investors in recent years [4]. Group 3: Case Specifics - The lawsuit alleges that Molina's management misrepresented the company's medical cost trend assumptions and financial guidance for fiscal year 2025, leading to investor damages when the true information was revealed [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Nidec Corporation due to allegations of materially misleading business information [1] Group 1: Investigation and Allegations - Nidec Corporation is facing scrutiny after a report indicated improper accounting practices within its China unit, leading to a significant drop in share prices [3] - Following the announcement of the probe, Nidec's American Depositary Receipts (ADRs) experienced a decline of 22.7% on September 4, 2025, marking the largest one-day drop for the company [3] Group 2: Class Action Details - Shareholders who purchased Nidec Corporation securities may be eligible for compensation through a class action lawsuit, with no out-of-pocket fees due to a contingency fee arrangement [2] - Interested investors can join the class action by submitting a form or contacting the law firm directly for more information [2] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company [4] - The firm has consistently ranked among the top in securities class action settlements, recovering hundreds of millions for investors, including over $438 million in 2019 alone [4]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Zions Bancorporation due to allegations of materially misleading business information issued by the company [1] Group 1: Legal Action and Investor Rights - Shareholders who purchased Zions Bancorporation securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2] - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the alleged misleading information [2] Group 2: Financial Impact and Company Disclosure - On October 15, 2025, Zions Bancorporation announced a $50 million charge-off for a loan due to misrepresentations and contractual defaults by borrowers [3] - Following this announcement, Zions Bancorporation's common stock experienced a decline of 13.14% on October 16, 2025 [4] Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [5] - The firm has been recognized as a leader in the field, being ranked No. 1 for securities class action settlements in 2017 and consistently in the top 4 since 2013 [5]

Core Viewpoint - Rosen Law Firm is encouraging investors of Baxter International Inc. to secure legal counsel before the December 15, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [2][3]. Group 1: Class Action Details - The class period for the lawsuit is from February 23, 2022, to July 30, 2025, and investors who purchased Baxter common stock during this time may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3][4]. - Investors wishing to serve as lead plaintiffs must file a motion with the court by December 15, 2025, to represent other class members in the litigation [4]. Group 2: Allegations Against Baxter - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which caused malfunctions that posed serious risks to patients [6]. - Specific issues cited include underinfusion, overinfusion, and complete non-delivery of fluids, along with inadequate remedial measures taken by Baxter despite being notified of multiple device malfunctions and associated injuries [6]. - The lawsuit claims that Baxter's statements regarding the safety, efficacy, and sales prospects of the Novum LVPs were materially false and misleading, leading to investor damages when the true details became public [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions of dollars for investors [5]. - The firm has been recognized for its leadership in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 alone [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of Molina Healthcare, Inc. who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the December 2, 2025 deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Molina securities between February 5, 2025, and July 23, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 2, 2025 [3]. - The lawsuit alleges that Molina failed to disclose several material adverse facts regarding its financial health and operational assumptions, which misled investors [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a record settlement against a Chinese company and significant recoveries for investors in previous years [4]. Group 3: Case Specifics - The lawsuit claims that Molina's financial guidance for fiscal year 2025 was likely to be cut due to undisclosed adverse facts, which included issues with medical cost trend assumptions and a dislocation between premium rates and medical costs [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Tandem Diabetes Care securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the misleading information [2]. Group 2: Incident Details - On August 7, 2025, Tandem Diabetes Care announced a voluntary medical device correction for select t:slim X2 insulin pumps due to a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following this announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved notable settlements, including the largest securities class action settlement against a Chinese company and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of Inspire Medical Systems, Inc. to secure legal counsel before the January 5, 2026 deadline for a class action lawsuit related to the company's stock performance during the specified class period [1][3]. Group 1: Class Action Details - The class period for the Inspire Medical Systems, Inc. stock is from August 6, 2024, to August 4, 2025, inclusive [1]. - Investors who purchased common stock during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and potential lead plaintiffs must act by January 5, 2026 [3]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]. Group 3: Case Allegations - The lawsuit alleges that Inspire Medical Systems misrepresented key facts about its Inspire V sleep apnea device, including market demand and readiness for launch, leading to misleading statements that inflated investor confidence [5].